Trial Profile

Window of Opportunity Trial to Evaluate Change in PD-L1 Expression in Triple Negative Breast Tumors in Response to the PARP Inhibitor Rucaparib

Status: Completed

Phase of Trial: Phase 0

Latest Information Update: 08 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rucaparib (Primary)
Indications Early breast cancer; Triple negative breast cancer
Focus Pharmacodynamics

Most Recent Events

03 Oct 2024 Status changed from active, no longer recruiting to completed.
04 Jun 2024 Results assessing Change in tumor microenvironment and PD-L1 expression with rucaparib treatment in triple-negative breast cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology
24 Feb 2022 Planned End Date changed from 30 Nov 2021 to 30 Nov 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com